



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54448

**Title:** Medications in type-2 diabetics and their association with liver fibrosis

**Reviewer’s code:** 00052643

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer’s Country/Territory:** Italy

**Author’s Country/Territory:** United States

**Manuscript submission date:** 2020-01-31

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-31 09:28

**Reviewer performed review:** 2020-02-03 11:48

**Review time:** 3 Days and 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

"Medications in Type-2 Diabetics And Their Association With Non-alcoholic Fatty Liver Disease Related Advanced Fibrosis" is an interesting article. Authors' findings are not only innovative, but also important as cited medications are very common in clinical practice and clinicians must be aware of their associations with advanced fibrosis. Overall, it is a good work. However I think some modifications concerning language and layout (not exactly compliant BPG guidelines) would be necessary before publication.



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54448

**Title:** Medications in type-2 diabetics and their association with liver fibrosis

**Reviewer’s code:** 00507108

**Position:** Peer Reviewer

**Academic degree:** FACP, FRCS (Ed), MD

**Professional title:** Professor, Doctor

**Reviewer’s Country/Territory:** Ireland

**Author’s Country/Territory:** United States

**Manuscript submission date:** 2020-01-31

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-02-03 18:29

**Reviewer performed review:** 2020-02-04 11:24

**Review time:** 16 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

29 January 2020 Correlation of leptin and Vaspin in newly diagnosed Type 2 Diabetes. The association of leptin with fat mass and insulin resistance is well known. The relationship between Leptin and atherosclerosis less definite but as the Authors write animal experiments suggest that this may be the case . I was unable to find ref 3 in Pub med but the Authors should distinguish between animal and human studies .. The Authors should consider a paragraph in the introduction on the impact of gender and menopause on Leptin and Vapin. The results are given in Tables and Figures but my copy did not have figures.. There is no text with a description of the results which is unusual. Tables and figures probably not sufficient for easy understanding of the findings. The Authors should consider a description of the main results in a text format as well as the tables and figures, in the results section rather than in the discussion and the discussion section becomes discussion of the results. It would be interesting to see a graph of leptin and Vaspin against BMI as compared to Waist/hip ratio as fat mass is better represented by waist/hip rather than BMI in Indians. I am not clear what the Authors mean when quoting Brennan . The Brennan paper does not discuss adipocyte dysfunction but is a report on the relationship between leptin and CVD,



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54448

**Title:** Medications in type-2 diabetics and their association with liver fibrosis

**Reviewer's code:** 03293832

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Senior Research Fellow

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** United States

**Manuscript submission date:** 2020-01-31

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-31 18:50

**Reviewer performed review:** 2020-02-05 03:13

**Review time:** 4 Days and 8 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

The manuscript describes the relationship between liver fibrosis and various medications in in patients with biopsy-proven NAFLD and type 2 diabetes using their own hospital records. Authors concluded 'being on metformin, liraglutide, lisinopril, hydrochlorothiazide, atorvastatin and simvastatin is associated with less likelihood of advanced fibrosis, while using furosemide and spironolactone increased the risk of advanced fibrosis'. The manuscript is well written and contents are novel and worth publication in WJG. I only suggest that authors avoid to declare 'using furosemide and spironolactone increased the risk of advanced fibrosis' and soften the expression, because there is a limitation of the present work as authors themselves mention in the last part of Discussion. Minor comments 1. Please write in full LKB1 (liver kinase B1) and HSCs (hepatic stellate cells). No abbreviation will be necessary because those words are used once in the text. 2. Please add the explanation of mo (month) in Table 2. 3. Please add the explanation of the numbers 81 and 325 in aspirin dose in Table 2.



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54448

**Title:** Medications in type-2 diabetics and their association with liver fibrosis

**Reviewer's code:** 01919991

**Position:** Peer Reviewer

**Academic degree:** MSc, PhD

**Professional title:** Research Scientist

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** United States

**Manuscript submission date:** 2020-01-31

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-31 05:18

**Reviewer performed review:** 2020-02-07 07:53

**Review time:** 7 Days and 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

The study by Siddiqui and coworkers is a retrospective cohort study to assess the association between master medications used in diabetes and advanced fibrosis in patients with biopsy-proven NAFLD and T2D. The topic is interesting given the prevalence of the two pathologies NAFLD and TD2 and the relationships between them. The quality of the manuscript is adequate and, although further studies are needed, the results could have a potential impact on the clinical practice of drug treatment of diabetic patients at risk or with overt NAFLD. In my opinion, for the sake of greater disclosure, the authors should extend the information on published studies on appropriate antidiabetic treatments (oral or injectable) that can improve NAFLD. I refer, citing only a few as an example: Hazlehurst et al, 2016, [doi.org/10.1016/j.metabol.2016.01.001](https://doi.org/10.1016/j.metabol.2016.01.001); Xia & Gao, 2019, [doi: 10.3389/fphar.2019.00877](https://doi.org/10.3389/fphar.2019.00877); Dharmalingam & Yamasandhi, 2018, [doi: 10.4103/ijem.IJEM\\_585\\_17](https://doi.org/10.4103/ijem.IJEM_585_17); [10.4103/ijem.IJEM\\_585\\_17](https://doi.org/10.4103/ijem.IJEM_585_17).



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54448

**Title:** Medications in type-2 diabetics and their association with liver fibrosis

**Reviewer's code:** 03293832

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Senior Research Fellow

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** United States

**Manuscript submission date:** 2020-01-31

**Reviewer chosen by:** Yu-Qiao Wang (Quit in 2020)

**Reviewer accepted review:** 2020-04-02 03:18

**Reviewer performed review:** 2020-04-02 06:18

**Review time:** 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

Authors addressed comments appropriately.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54448

**Title:** Medications in type-2 diabetics and their association with liver fibrosis

**Reviewer's code:** 00052643

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** United States

**Manuscript submission date:** 2020-01-31

**Reviewer chosen by:** Yu-Qiao Wang (Quit in 2020)

**Reviewer accepted review:** 2020-04-02 08:20

**Reviewer performed review:** 2020-04-02 08:25

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

The paper is now suitable for publication, as authors have done the suggested



# Baishideng Publishing Group

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

modifications.